Hemangioblastomas

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2012-05-11
Clinical Trial Update: Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease [EARLY_Phase 1]
A Phase 1 trial of bevacizumab (Avastin) for unresectable or recurrent hemangioblastomas in Von Hippel-Lindau disease has been terminated.